The Combination of L-lysine and Alloxan Induces Acute Necrotizing Pancreatitis in Rats: A Recent Study | Chapter 6 | Challenges in Disease and Health Research Vol. 9

 The goal of this research was to see how L-lysine affected the pancreas of diabetic rats. Adult male Sprague-Dawley rats were split into four groups (each with six rats) and studied for 20 days. Control Group I (saline solution, i.p.). Group II: L-lysine (10 mM)-treated rats. Group III: Rats given 120 mg/kg of alloxan (diabetic control). Group IV: Alloxan plus L-lysine-treated rats. The glucose, triglyceride, and cholesterol levels were measured using blood taken from the aorta. As expected, glucose levels in Group III rats increased. Body weight decrease was also found (p 0.001). On the tenth day of the trial, diabetic control rats had greater glucose concentrations than rats in Group IV. L-lysine given to intact animals had an effect on the pancreas, according to the findings. Animals who have previously received alloxan injections exhibited more pancreatic damage. Hyperglycemia was clearly caused by a single dose of L-lysine. This impact is increased when L-lysine is coupled with alloxan.

We can now offer a new rat model of acute pancreatitis based on these findings.

Author (S) Details

José D. Méndez
Medical Research Unit in Metabolic Diseases, Cardiology Hospital, National Medical Center, Mexican Institute of Social Security, México

Jianling Xie
Nutrition and Metabolism South Australia Health & Medical Research Institute, Adelaide, Australia.

Verna Méndez-Valenzuela
General Hospital 49, Mexican Institute of Social Security, Los Mochis, Sinaloa, México.

José L. Martínez
Department of General and Gastrointestinal Surgery, Specialities Hospital, National Medical Center, Mexican Institute of Social Security, México.

View Book :- https://stm.bookpi.org/CDHR-V9/article/view/2060

A Brief Review on Gestational Diabetes Mellitus | Chapter 1 | Technological Innovation in Pharmaceutical Research Vol. 4

 GDM (gestational diabetes mellitus) is a common metabolic disorder that can occur before or during pregnancy in varied degrees of severity. It's been related to poor mother and neonatal health. The prevalence of GDM is increasing globally, along with the increase of obesity and type 2 diabetes mellitus. GDM must be detected and treated as soon as feasible to reduce or eliminate complications for both the mother and the foetus. There is a lack of consistency in evaluating and detecting GDM on a global scale. The latest current advancements in the diagnosis and treatment of GDM are discussed in this article. Treatment must be personalised to the individual, including medical nutrition therapy, additional diet, and exercise for the best results. Pharmacologic therapy, such as insulin and its analogues, should be used if these treatments fail to control blood glucose levels. Treatment with pharmacologic therapies plays an essential role in reducing GDM-related problems. In view of new evidence on the safety and efficacy of oral antihyperglycemic medications like Metformin and Glyburide during pregnancy, other oral antihyperglycemic medications like Metformin and Glyburide are also being considered.

Author (s) Details

Sachin B. Somwanshi
Department of Pharmaceutics, P.R.E.S.’s, College of Pharmacy (For Women), Chincholi, Tal: Sinnar, Dist: Nashik, Maharashtra, 422102, India.

Kiran B. Kotade
Department of Pharmacology, P.R.E.S.’s, College of Pharmacy (For Women), Chincholi, Tal: Sinnar, Dist: Nashik, Maharashtra, 422102, India.

View Book :- https://stm.bookpi.org/TIPR-V4/article/view/1493

Postprandial Effects of a Proprietary Milk Protein Hydrolysate Containing Bioactive Peptides in Prediabetic Subjects: A Recent Study | Chapter 10 | Highlights on Medicine and Medical Research Vol. 7

 Milk proteins are thought to protect against type 2 diabetes (T2DM) through regulating the glycemic response, particularly in the postprandial state. The high content of whey proteins, which are usually a byproduct of cheese production, is one reason for this possibility. Milk contains two protein fractions: casein, which is slowly digesting, and whey, which is quickly digestible. However, because of its increased leucine content, native whey has gotten a lot of attention, and its postprandial glycemic effect in prediabetes has yet to be determined. In this study, prediabetics were given a randomised, cross-over trial to see how effective a milk protein hydrolysate of native whey origin with alpha-glucosidase inhibitory capabilities was. Prior to a high-carbohydrate challenge meal, subjects were given a single dosage of placebo, low-dosed milk protein hydrolysate, or high-dosed milk protein hydrolysate. Glucose and insulin concentration-time curves were examined. Low-dosed milk peptides significantly reduced incremental areas under the curve (iAUC) of glucose as the primary endpoint compared to placebo (P = 0.0472), and a slight insulinotropic effect was observed. A longer intervention period with the low-dosed product did not improve glucose response but did reduce HbA1c levels significantly (P = 0.0244). To summarise, the current milk protein hydrolysate of native whey origin has the potential to modify postprandial hyperglycemia and hence may help to reduce the risk of developing T2DM in the future.

Author(s) Details

Tina Sartorius
BioTeSys GmbH, Division Clinical Studies, Esslingen, Germany.

Andrea Weidner
BioTeSys GmbH, Schelztorstr. 54–56, 73728 Esslingen, Germany.

Tanita Dharsono
BioTeSys GmbH, Schelztorstr. 54–56, 73728 Esslingen, Germany.

Audrey Boulier
Ingredia S.A., 51 Avenue F. Lobbedez CS 60946, 62033 Arras CEDEX, France.

Manfred Wilhelm
Department of Mathematics, Natural and Economic Sciences, Ulm University of Applied Sciences, Albert-Einstein-Allee 55, 89081 Ulm, Germany.

Christiane Schön
BioTeSys GmbH, Schelztorstr. 54–56, 73728 Esslingen, Germany.

View Book :- https://stm.bookpi.org/HMMR-V7/article/view/1065